Examining The Emergence Of Unit- & Bi-Dose Nasal Sprays
Source: Catalent

Molecules that are limited by a slow onset of action, a suboptimal side-effect profile, or a complicated administration process, may be good candidates for adaptation to a unit- or bi-dose nasal delivery format. This is especially true for drugs targeting the central nervous system (CNS). Established molecules may also benefit from shorter development timelines and regulatory review cycles.
Nasal spray administration of medicine offers advantages over oral and intravenous (IV) delivery. Catalent’s Andrew Samuelsson, Craig Davies-Cutting and Tom Clark discuss the advantages and opportunities of adopting unit- and bi-dose nasal delivery technology.
VIEW THE Q&A!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Outsourced Pharma? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Catalent
This website uses cookies to ensure you get the best experience on our website. Learn more